CTI BioPharma   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Seattle WA United States (1991)

Organization Overview

First Clinical Trial
1998
NCT00004026
First Marketed Drug
2000
arsenic trioxide (trisenox)
First NDA Approval
2000
arsenic trioxide (trisenox)
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Cell Therapeutics | CTI BioPharma | CTI Clinical Trial & Consulting Services

Active Ingredients

Marketed Drugs (1)

arsenic trioxide (trisenox) (2000 NDA)

Drugs in Phase 3 Trials (17)

Key: CTI BioPharma (16) Acquired (1)

carboplatin (paraplatin) (5 trials)

cyclophosphamide (cytoxan) (4 trials)

docetaxel (taxotere) (1 trial)

etoposide (vepesid) (1 trial)

fludarabine (fludara) (4 trials)

gemcitabine (gemzar) (4 trials)

ibritumomab tiuxetan (Zevalin) (3 trials)

ifosfamide (ifex) (1 trial)

mitoxantrone (novantrone) (1 trial)

oxaliplatin (eloxatin) (1 trial)

paclitaxel (taxol) (13 trials)

pacritinib (Vonjo) (28 trials)

pixuvri (12 trials)

prednisone (meticorten) (3 trials)

rituximab (rituxan) (10 trials)

vincristine (oncovin) (3 trials)

vinorelbine (navelbine) (2 trials)

Drugs in Phase 2 Trials (28)

Key: CTI BioPharma (25) Acquired (3)

allogeneic stem cells (1 trial)

arsenic trioxide (trisenox) (9 trials)

azacitidine (vidaza) (4 trials)

bendamustine (treanda) (1 trial)

brostallicin (1 trial)

busulfan (Myleran) (1 trial)

capecitabine (xeloda) (1 trial)

cetuximab (erbitux) (1 trial)

ct-2584 (1 trial)

cytarabine (cytosar-u) (2 trials)

decitabine (dacogen) (3 trials)

doxorubicin (Doxil) (2 trials)

fluorouracil (efudex) (1 trial)

leucovorin (1 trial)

melphalan (alkeran) (1 trial)

naltrexone (revia) (1 trial)

obinutuzumab (gazyva) (1 trial)

pemetrexed (alimta) (1 trial)

polyglutamate camptothecin (2 trials)

pracinostat (2 trials)

sirolimus (rapamune) (1 trial)

sulfated oxysterol (2 trials)

tacrolimus (prograf) (1 trial)

temozolomide (temodar) (1 trial)

thalidomide (Thalomid) (1 trial)

tosedostat (3 trials)

urea (2 trials)

vitamin c (1 trial)

Drugs in Phase 1 Trials (6)

Key: CTI BioPharma (5) Acquired (1)

clarithromycin (biaxin) (1 trial)

daunorubicin (cerubidine) (1 trial)

moxifloxacin (avelox) (1 trial)

rifampin (1 trial)

sb1578 (1 trial)

sodium chloride (1 trial)

Indications

Approved Indications


 

Leukemia, Promyelocytic, Acute

Experimental Indications (Clinical Trials, Phases 1-4)


 

Aggression (Phase 3)

Brain Neoplasms (Phase 1)

Breast Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Central Nervous System Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 2)

Glioma (Phase 2)

Graft vs Host Disease (Phase 2)

Head and Neck Neoplasms (Phase 2)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis, Alcoholic (Phase 2)

Leukemia (Phase 3)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 1)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (Phase 1)

Leukemia, Myelomonocytic, Acute (Phase 1)

Leukemia, Myelomonocytic, Chronic (Phase 1)

Leukemia, Myelomonocytic, Juvenile (Phase 1)

Liposarcoma (Phase 2)

Liposarcoma, Myxoid (Phase 2)

Lung Neoplasms (Phase 3)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 3)

Lymphoma, Follicular (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Lymphoma, Non-Hodgkin (Phase 3)

Multiple Myeloma (Phase 2)

Myelodysplastic-Myeloproliferative Diseases (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Myeloproliferative Disorders (Phase 2)

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Neoplasms, Second Primary (Phase 1)

Nervous System Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 2)

Plasmacytoma (Phase 2)

Polycythemia (Phase 3)

Polycythemia Vera (Phase 3)

Preleukemia (Phase 2)

Primary Myelofibrosis (Phase 3)

Prostatic Neoplasms (Phase 2)

Syndrome (Phase 2)

Thrombocythemia, Essential (Phase 3)

Thrombocytopenia (Phase 3)

Thrombocytosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 77
  • # of Trial APIs: 51